At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 19 enrolled
Drug / intervention
AbobotulinumtoxinA (ABO) +1 moredrug
Likely dose
AbobotulinumtoxinA (ABO) 0.02 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Fields of Effects of Two Commercial Preparations of Botulinum Toxin Type A at Equal Labeled Unit Doses
In Brief
A Phase 4 clinical trial evaluating AbobotulinumtoxinA (ABO) and OnabotulinumtoxinA (ONA) for Skin Wrinkling. Completed, enrolled 19 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the fields of anhydrotic effect (FAE) of abobotulinumtoxinA and onabotulinumtoxinA at the same labeled unit dose (1:1 units), comparing both sweat gland and muscle activity.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSkin Wrinkling
CountriesBrazil
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2011
Primary CompletionNov 2011
First PostedNov 2012
TodayJul 2026
First PostedNov 26, 2012
Enrollment StartJan 1, 2011
Primary CompletionNov 1, 2011
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 13.6 years ago
Interventions
AbobotulinumtoxinA (ABO)drug
Isovolumetric (0.02 mL) doses of 2 units of abobotulinumtoxinA injected on one side of the forehead.
OnabotulinumtoxinA (ONA)drug
Isovolumetric (0.02 mL) doses of 2 units of onabotulinumtoxinA injected on the other side of the forehead.